Meet Us at the 13th Alzheimer’s & Parkinson’s Drug Development Summit

In 2025, the spotlight is on neurodegenerative drug development, driven by the triumph of Lecanemab and Donanemab, coupled with rapid advancements to enable presymptomatic diagnosis, reinvigorating the space with new targets, modalities, and technologies. Meanwhile significant advancements to target the likes of α-synuclein, NLRP3 and GBA suggest only a matter of time until a disease-modifying therapy emerges on the scene for Parkinson’s too.

Capitalizing on a new era of revitalized hope and momentum, the 13th Alzheimer’s & Parkinson’s Drug Development Summit returns as the only industry-focused and end-to-end meeting, with comprehensive coverage spanning early discovery through to late clinical, regulatory, and commercial development.

The 13th Alzheimer’s & Parkinson’s Drug Development Summit has ended. Thank you all for your enthusiastic attention to our booth and look forward to seeing you at the next Alzheimer’s & Parkinson’s Drug Development Summit.

Creative Biolabs is proud to exhibit and participate in industry conferences where our scientists showcase innovative drug discovery solutions. Whether you are diving into scientific research, biopharmaceutical discovery and development, or industrial manufacturing, we strongly encourage you to come and meet us at our upcoming conferences!